CA3205490A1 - Use of pharmaceutical composition for treating lung cancer - Google Patents
Use of pharmaceutical composition for treating lung cancerInfo
- Publication number
- CA3205490A1 CA3205490A1 CA3205490A CA3205490A CA3205490A1 CA 3205490 A1 CA3205490 A1 CA 3205490A1 CA 3205490 A CA3205490 A CA 3205490A CA 3205490 A CA3205490 A CA 3205490A CA 3205490 A1 CA3205490 A1 CA 3205490A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- och3
- pharmaceutical composition
- formula
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 43
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 28
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 27
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 141
- 230000012010 growth Effects 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 50
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 32
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 32
- 229940121647 egfr inhibitor Drugs 0.000 claims description 28
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 claims description 14
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 claims description 13
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims description 13
- 229940125878 compound 36 Drugs 0.000 claims description 13
- 229940125807 compound 37 Drugs 0.000 claims description 13
- 229960003278 osimertinib Drugs 0.000 claims description 13
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 13
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 11
- 229960002584 gefitinib Drugs 0.000 claims description 11
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 claims description 6
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims description 6
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims description 6
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims description 6
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 6
- 229940126639 Compound 33 Drugs 0.000 claims description 6
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims description 6
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 6
- 229940125846 compound 25 Drugs 0.000 claims description 6
- 229940125851 compound 27 Drugs 0.000 claims description 6
- 229940125877 compound 31 Drugs 0.000 claims description 6
- 125000000468 ketone group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- SLTBMTIRYMGWLX-XMMPIXPASA-N (2r)-2-[(4-chloroanilino)carbamoylamino]-3-(1h-indol-3-yl)-n-(2-phenylethyl)propanamide Chemical compound C1=CC(Cl)=CC=C1NNC(=O)N[C@@H](C(=O)NCCC=1C=CC=CC=1)CC1=CNC2=CC=CC=C12 SLTBMTIRYMGWLX-XMMPIXPASA-N 0.000 claims description 5
- RXCVUHMIWHRLDF-HXUWFJFHSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-HXUWFJFHSA-N 0.000 claims description 5
- 125000002587 enol group Chemical group 0.000 claims description 5
- 229910019567 Re Re Inorganic materials 0.000 claims description 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
- 229960001686 afatinib Drugs 0.000 claims description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
- 101100172748 Mus musculus Ethe1 gene Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 91
- 206010028980 Neoplasm Diseases 0.000 description 47
- 238000011282 treatment Methods 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 27
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- 230000035772 mutation Effects 0.000 description 12
- 229940109262 curcumin Drugs 0.000 description 11
- 235000012754 curcumin Nutrition 0.000 description 11
- 239000004148 curcumin Substances 0.000 description 11
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 8
- 206010071975 EGFR gene mutation Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 101150039808 Egfr gene Proteins 0.000 description 5
- 108700021358 erbB-1 Genes Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- PTBDIHRZYDMNKB-UHFFFAOYSA-M 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate Chemical compound OCC(C)(CO)C([O-])=O PTBDIHRZYDMNKB-UHFFFAOYSA-M 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- -1 methoxy-5,1-phenylene Chemical group 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- VEKIZRLWPXYFMW-UHFFFAOYSA-N hepta-1,6-diene-3,5-dione Chemical group C=CC(=O)CC(=O)C=C VEKIZRLWPXYFMW-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A use of a pharmaceutical composition is provided. The pharmaceutical composition contains a diarylheptanoid compound or a pharmaceutically acceptable salt thereof. The diarylheptanoid compound has a structure shown in formula (I). Symbols in formula (I) are as defined in the description, and the pharmaceutical composition can inhibit the growth of lung cancer cells. Therefore, the pharmaceutical composition can be used for preparing a drug for treating lung cancer.
Description
USE OF PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER
Technical Field The present disclosure relates to a use of a pharmaceutical composition. More particularly, the present disclosure relates to a use of a pharmaceutical composition including a diarylheptanoid compound or a pharmaceutically acceptable salt thereof for treating lung cancer.
Description of Related Art Cancer, also known as malignant tumor, is an abnormal proliferation of cells, and these proliferating cells may invade other parts of the body, which is a disease caused by abnormal control of cell division and proliferation mechanisms. There is an increasing trend in the number of people suffering from cancer worldwide, and about 20% of the cancer population in the world is lung cancer patients. The 5-year survival rate of lung cancer patients after treatment is still as low as about 15%, which has been the cancer with the highest death rate in the world for many years.
According to different biological characteristics, treatment and prognosis, lung cancer can be divided into small cell lung cancer and non-small cell lung cancer (NSCLC).
About 85-90% of lung cancers are NSCLC, of which lung adenocarcinoma is the most common type of lung cancer in women and non-smoking patients. Treatment for lung cancer often depends on the age of patient, past medical history, current health status, type of cancer cells, and stage of the disease.
Generally speaking, small cell lung cancer has the characteristics of rapid division Date Regue/Date Received 2023-06-16 and proliferation, and metastases may occur in a short period of time, so that systemic chemotherapy or radiation therapy is the main treatment. The growth of NSCLC
is slower, and the occurrence of metastasis is also slower, so that the principle of treatment depends on the clinical stage of the disease. The radical treatment of early stage (stage I, II) NSCLC is still based on complete resection of the tumor by surgery. The treatment principle is mainly chemical drug therapy or chemical drug combined with radiation therapy for the locally extended stage (stage III) including patients with malignant pericardium or hydropleural effusion and distant metastases (stage IV) or patients whose physical condition cannot be surgically removed.
However, it is a thorny problem in the treatment of metastatic or advanced NSCLC that has undergone chemotherapy and relapsed. Current clinical studies have confirmed that epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) can be used as the second-line treatment after the first-line chemotherapy fails. But about 40-80% of NSCLC patients have the EGFR gene mutation, which overexpresses the epidermal growth factor receptor, leading to rapid growth, metastasis and drug resistance of cancer. Almost all patients with the EGFR
gene mutation relapse within two years after clinical treatment with EGFR-TKIs, and no effective drugs are available after relapse so far.
SUMMARY
In view of this, one of the objectives of the present disclosure is to provide a use of a pharmaceutical composition, which can be used to manufacture a drug for treating a lung cancer. The pharmaceutical composition includes a diarylheptanoid
Technical Field The present disclosure relates to a use of a pharmaceutical composition. More particularly, the present disclosure relates to a use of a pharmaceutical composition including a diarylheptanoid compound or a pharmaceutically acceptable salt thereof for treating lung cancer.
Description of Related Art Cancer, also known as malignant tumor, is an abnormal proliferation of cells, and these proliferating cells may invade other parts of the body, which is a disease caused by abnormal control of cell division and proliferation mechanisms. There is an increasing trend in the number of people suffering from cancer worldwide, and about 20% of the cancer population in the world is lung cancer patients. The 5-year survival rate of lung cancer patients after treatment is still as low as about 15%, which has been the cancer with the highest death rate in the world for many years.
According to different biological characteristics, treatment and prognosis, lung cancer can be divided into small cell lung cancer and non-small cell lung cancer (NSCLC).
About 85-90% of lung cancers are NSCLC, of which lung adenocarcinoma is the most common type of lung cancer in women and non-smoking patients. Treatment for lung cancer often depends on the age of patient, past medical history, current health status, type of cancer cells, and stage of the disease.
Generally speaking, small cell lung cancer has the characteristics of rapid division Date Regue/Date Received 2023-06-16 and proliferation, and metastases may occur in a short period of time, so that systemic chemotherapy or radiation therapy is the main treatment. The growth of NSCLC
is slower, and the occurrence of metastasis is also slower, so that the principle of treatment depends on the clinical stage of the disease. The radical treatment of early stage (stage I, II) NSCLC is still based on complete resection of the tumor by surgery. The treatment principle is mainly chemical drug therapy or chemical drug combined with radiation therapy for the locally extended stage (stage III) including patients with malignant pericardium or hydropleural effusion and distant metastases (stage IV) or patients whose physical condition cannot be surgically removed.
However, it is a thorny problem in the treatment of metastatic or advanced NSCLC that has undergone chemotherapy and relapsed. Current clinical studies have confirmed that epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) can be used as the second-line treatment after the first-line chemotherapy fails. But about 40-80% of NSCLC patients have the EGFR gene mutation, which overexpresses the epidermal growth factor receptor, leading to rapid growth, metastasis and drug resistance of cancer. Almost all patients with the EGFR
gene mutation relapse within two years after clinical treatment with EGFR-TKIs, and no effective drugs are available after relapse so far.
SUMMARY
In view of this, one of the objectives of the present disclosure is to provide a use of a pharmaceutical composition, which can be used to manufacture a drug for treating a lung cancer. The pharmaceutical composition includes a diarylheptanoid
2 Date Regue/Date Received 2023-06-16 compound or a pharmaceutically acceptable salt thereof, which can inhibit the growth of the epidermal growth factor receptor-tyrosine kinase inhibitors resistant non-small cell lung cancer cells. Therefore, the pharmaceutical composition can be used alone or in combination with clinically used epidermal growth factor receptor-tyrosine kinase inhibitors to treat a EGFR gene mutation with epidermal growth factor receptor-tyrosine kinase inhibition drug-resistant lung cancer.
According to one aspect of the present disclosure is to provide a use of a pharmaceutical composition, the pharmaceutical composition is used to manufacture a drug for treating a lung cancer, wherein the pharmaceutical composition includes a diarylheptanoid compound or a pharmaceutically acceptable salt thereof, the diarylheptanoid compound has a structure represented by Formula (I):
Ra R ' a RC Rc Rb Rbi Re Re Formula (I), wherein Ra, Rb, Ra' and Rh' are independently H, C1-C2 alkyl, C1-C3 alkoxy, OH, or -0C(=0)Rd, wherein Rd is C1-C3 alkyl or C1-C3 alkanol; Rc is H, C1-C2 alkyl, C3-C6 unsaturated alkyl or C7-C12 arylalkyl with double or triple bonds; and Re and Re' are independently H, C1-C6 alkyl or C1-C6 alkoxy.
According to the use of the pharmaceutical composition, wherein at least one of Ra, Rh, Ra', and Rh' can be -0C(=0)Rd, wherein Rd is C1-C3 alkyl or C1-C3 alkanol.
According to one aspect of the present disclosure is to provide a use of a pharmaceutical composition, the pharmaceutical composition is used to manufacture a drug for treating a lung cancer, wherein the pharmaceutical composition includes a diarylheptanoid compound or a pharmaceutically acceptable salt thereof, the diarylheptanoid compound has a structure represented by Formula (I):
Ra R ' a RC Rc Rb Rbi Re Re Formula (I), wherein Ra, Rb, Ra' and Rh' are independently H, C1-C2 alkyl, C1-C3 alkoxy, OH, or -0C(=0)Rd, wherein Rd is C1-C3 alkyl or C1-C3 alkanol; Rc is H, C1-C2 alkyl, C3-C6 unsaturated alkyl or C7-C12 arylalkyl with double or triple bonds; and Re and Re' are independently H, C1-C6 alkyl or C1-C6 alkoxy.
According to the use of the pharmaceutical composition, wherein at least one of Ra, Rh, Ra', and Rh' can be -0C(=0)Rd, wherein Rd is C1-C3 alkyl or C1-C3 alkanol.
3 Date Recue/Date Received 2023-06-16 According to the use of the pharmaceutical composition, wherein the diarylheptanoid compound can be interconvertible between keto and enol forms, when Rc is H.
According to the use of the pharmaceutical composition, wherein the diarylheptanoid compound can be selected from Compound 1, Compound 21a, Compound 21b, Compound 22a, Compound 22b, Compound 23a, Compound 23b, Compound 24a, Compound 24b, Compound 25, Compound 26, Compound 27, Compound 31 and Compound 33 having a structure represented by Formula (II):
nn R3 rs.3 Formula (II);
wherein Ri, Ri' are OCH3 respectively, R2, R2' are H respectively, R3, R3' are H
respectively in Compound 1; Ri, Ri' are OCH3 respectively, R2, R2' are 0R4 respectively, R3, R3' are H respectively in Compound 21a; Ri, Ri' are OCH3 respectively, R2 is OH, R2' is 0R4, R3, R3' are H respectively in Compound 21b; Ri, Ri' are OCH3 respectively, R2, R2' are 0R5 respectively, R3, R3' are H
respectively in Compound 22a; Ri, Ri' are OCH3 respectively, R2 is OH, R2' is 0R5, R3, R3' are H
respectively in Compound 22b; Ri, Ri' are H respectively, R2, R2' are 0R5 respectively, R3, R3' are H respectively in Compound 23a; Ri, Ri' are H
respectively, R2 is 0R5, R2' is OH, R3, R3' are H respectively in Compound 23b; Ri, Ri' are
According to the use of the pharmaceutical composition, wherein the diarylheptanoid compound can be selected from Compound 1, Compound 21a, Compound 21b, Compound 22a, Compound 22b, Compound 23a, Compound 23b, Compound 24a, Compound 24b, Compound 25, Compound 26, Compound 27, Compound 31 and Compound 33 having a structure represented by Formula (II):
nn R3 rs.3 Formula (II);
wherein Ri, Ri' are OCH3 respectively, R2, R2' are H respectively, R3, R3' are H
respectively in Compound 1; Ri, Ri' are OCH3 respectively, R2, R2' are 0R4 respectively, R3, R3' are H respectively in Compound 21a; Ri, Ri' are OCH3 respectively, R2 is OH, R2' is 0R4, R3, R3' are H respectively in Compound 21b; Ri, Ri' are OCH3 respectively, R2, R2' are 0R5 respectively, R3, R3' are H
respectively in Compound 22a; Ri, Ri' are OCH3 respectively, R2 is OH, R2' is 0R5, R3, R3' are H
respectively in Compound 22b; Ri, Ri' are H respectively, R2, R2' are 0R5 respectively, R3, R3' are H respectively in Compound 23a; Ri, Ri' are H
respectively, R2 is 0R5, R2' is OH, R3, R3' are H respectively in Compound 23b; Ri, Ri' are
4 Date Recue/Date Received 2023-06-16 respectively, R2, R2' are OCH3 respectively, R3, R3' are H respectively in Compound 24a; Ri is 0R4, Ri' is OH, R2, R2' are OCH3 respectively, R3, R3' are H
respectively in Compound 24b; Ri is 0R5, Ri' is OH, R2, R2' are OCH3 respectively, R3, R3' are H
respectively in Compound 25; Ri, Ri' are 0C2H5 respectively, R2, R2' are 0R4 .. respectively, R3, R3' are H respectively in Compound 26; Ri, Ri' are 0C2H5 respectively, R2, R2' are 0R5 respectively, R3, R3' are H respectively in Compound 27;
Ri, Ri' are C2H5 respectively, R2, R2' are 0R5 respectively, R3, R3' are C2H5 respectively in Compound 31; and Ri, Ri' are OCH3 respectively, R2 is OCH3, R2' is 0R4, R3, R3' are H respectively in Compound 33; wherein R4 is a structure represented by Formula (i), and R5 is a structure represented by Formula (ii):
OH OH
Formula (i); Formula (ii).
According to the use of the pharmaceutical composition, wherein the diarylheptanoid compound is selected from Compound 35a, Compound 35c, Compound 35d, Compound 35e, Compound 36 and Compound 37 having a structure represented by Formula (III):
R6 R6' '=,, Formula (III);
respectively in Compound 24b; Ri is 0R5, Ri' is OH, R2, R2' are OCH3 respectively, R3, R3' are H
respectively in Compound 25; Ri, Ri' are 0C2H5 respectively, R2, R2' are 0R4 .. respectively, R3, R3' are H respectively in Compound 26; Ri, Ri' are 0C2H5 respectively, R2, R2' are 0R5 respectively, R3, R3' are H respectively in Compound 27;
Ri, Ri' are C2H5 respectively, R2, R2' are 0R5 respectively, R3, R3' are C2H5 respectively in Compound 31; and Ri, Ri' are OCH3 respectively, R2 is OCH3, R2' is 0R4, R3, R3' are H respectively in Compound 33; wherein R4 is a structure represented by Formula (i), and R5 is a structure represented by Formula (ii):
OH OH
Formula (i); Formula (ii).
According to the use of the pharmaceutical composition, wherein the diarylheptanoid compound is selected from Compound 35a, Compound 35c, Compound 35d, Compound 35e, Compound 36 and Compound 37 having a structure represented by Formula (III):
R6 R6' '=,, Formula (III);
5 Date Recue/Date Received 2023-06-16 wherein R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is CH3 in Compound 35a; R6, R6' are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is benzyl in Compound 35c; R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is propargyl in Compound 35d; R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is allyl in Compound 35e; R6, Re are H respectively, R7, R7' are 0R4 respectively, R8 is CH3 in Compound 36; and R6, Re are 0R4 respectively, R7, R7' are OCH3 respectively, R8 is CH3 in Compound 37; wherein R4 is a structure represented by Formula (i):
'''jts's4:0H
OH
Formula (i).
According to the use of the pharmaceutical composition, wherein the diarylheptanoid compound can be selected from:
. 0 Ai mectsoõ J ( .H Ofis 0 '-1 Mg __ He>510 IP 7\ ' W-1-le'"irk0 ---HO ii HO
"'OH , ''.
He>ft0L
11 'EOH Ho=-=>)., 1-cii0H
HO OH HO
,and o o 0 110">fk0 rigki 'N, ..--- OH
IHO Rip 40 ' If'OH
i-t3c0 OCH3 .
'''jts's4:0H
OH
Formula (i).
According to the use of the pharmaceutical composition, wherein the diarylheptanoid compound can be selected from:
. 0 Ai mectsoõ J ( .H Ofis 0 '-1 Mg __ He>510 IP 7\ ' W-1-le'"irk0 ---HO ii HO
"'OH , ''.
He>ft0L
11 'EOH Ho=-=>)., 1-cii0H
HO OH HO
,and o o 0 110">fk0 rigki 'N, ..--- OH
IHO Rip 40 ' If'OH
i-t3c0 OCH3 .
6 Date Recue/Date Received 2023-06-16 According to the use of the pharmaceutical composition, wherein the pharmaceutical composition can further include epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Preferably, the EGFR-TKIs can be osimertinib, gefitinib, erlotinib or afatinib.
According to the use of the pharmaceutical composition, wherein the lung cancer can be a non-small cell lung cancer (NSCLC).
According to the use of the pharmaceutical composition, wherein the lung cancer can be resistant to epidermal growth factor receptor-tyrosine kinase inhibitors.
The above summary is intended to provide a simplified summary of the disclosure to provide the reader with a basic understanding of the disclosure.
The summary is not an exhaustive overview of the disclosure, and it is not intended to identify key/critical elements of embodiments of the present disclosure or to delineate the scope of the present disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
The present disclosure can be more fully understood by reading the following detailed description of the embodiment, with reference made to the accompanying drawings as follows:
Fig. 1A shows the analysis result of the inhibition of H1650 cell growth by the diarylheptanoid compounds of the present disclosure;
Fig. 1B, Fig. 1C and Fig. 1D show the analysis results of the inhibition of the growth of the epidermal growth factor receptor-tyrosine kinase inhibitors resistant
According to the use of the pharmaceutical composition, wherein the lung cancer can be a non-small cell lung cancer (NSCLC).
According to the use of the pharmaceutical composition, wherein the lung cancer can be resistant to epidermal growth factor receptor-tyrosine kinase inhibitors.
The above summary is intended to provide a simplified summary of the disclosure to provide the reader with a basic understanding of the disclosure.
The summary is not an exhaustive overview of the disclosure, and it is not intended to identify key/critical elements of embodiments of the present disclosure or to delineate the scope of the present disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
The present disclosure can be more fully understood by reading the following detailed description of the embodiment, with reference made to the accompanying drawings as follows:
Fig. 1A shows the analysis result of the inhibition of H1650 cell growth by the diarylheptanoid compounds of the present disclosure;
Fig. 1B, Fig. 1C and Fig. 1D show the analysis results of the inhibition of the growth of the epidermal growth factor receptor-tyrosine kinase inhibitors resistant
7 Date Regue/Date Received 2023-06-16 non-small cell lung cancer (NSCLC) cells by the diarylheptanoid compounds of the present disclosure;
Fig. 2A shows the analysis result of the inhibition of tumor growth in the GR6 tumor mice by treating Compound 35d alone;
Fig. 2B shows the analysis result of the inhibition of tumor growth in the GR8 tumor mice by treating Compound 35d alone;
Fig. 2C shows the analysis result of the inhibition of tumor growth in the tumor mice by treating Compound 35d alone;
Fig. 2D shows the statistical chart of body weight changes in the tumor mice by io treating Compound 35d alone;
Fig. 3A shows the analysis result of the inhibition of tumor re-progression in the GR6 tumor mice by treating a combined treatment of Compound 35d and osimertinib;
and Fig. 3B shows the statistical chart of body weight changes in the GR6 tumor mice by treating the combined treatment of Compound 35d and osimertinib.
DETAILED DESCRIPTION
The present disclosure provides a novel use of a pharmaceutical composition, and the pharmaceutical composition includes a diarylheptanoid compound or a pharmaceutically acceptable salt thereof, which can be used to manufacture a drug for treating a lung cancer. The diarylheptanoid compound of the present disclosure has a structure represented by Formula (I):
Fig. 2A shows the analysis result of the inhibition of tumor growth in the GR6 tumor mice by treating Compound 35d alone;
Fig. 2B shows the analysis result of the inhibition of tumor growth in the GR8 tumor mice by treating Compound 35d alone;
Fig. 2C shows the analysis result of the inhibition of tumor growth in the tumor mice by treating Compound 35d alone;
Fig. 2D shows the statistical chart of body weight changes in the tumor mice by io treating Compound 35d alone;
Fig. 3A shows the analysis result of the inhibition of tumor re-progression in the GR6 tumor mice by treating a combined treatment of Compound 35d and osimertinib;
and Fig. 3B shows the statistical chart of body weight changes in the GR6 tumor mice by treating the combined treatment of Compound 35d and osimertinib.
DETAILED DESCRIPTION
The present disclosure provides a novel use of a pharmaceutical composition, and the pharmaceutical composition includes a diarylheptanoid compound or a pharmaceutically acceptable salt thereof, which can be used to manufacture a drug for treating a lung cancer. The diarylheptanoid compound of the present disclosure has a structure represented by Formula (I):
8 Date Regue/Date Received 2023-06-16 Re R ' a I
Rc Rc I , Re Re Formula (I), wherein Ra, Rb, Rai and RID' are independently H, C1-C2 alkyl, C1-C3 alkoxy, OH, or -0C(=0)Rd, wherein Rd is C1-C3 alkyl or C1-C3 alkanol; Rc is H, C1-C2 alkyl, .. C3-C6 unsaturated alkyl or C7-C12 arylalkyl with double or triple bonds;
and Re and Re' are independently H, C1-C6 alkyl or C1-C6 alkoxy.
At least one of Ra, Rb, Rai, and RID' of the diarylheptanoid compound of the present disclosure can be -0C(=0)Rd, and Rd is C1-C3 alkyl or C1-C3 alkanol. In addition, the diarylheptanoid compound can be interconvertible between keto and enol forms, when Rc is H.
The pharmaceutical composition of the present disclosure can further include epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs), which can be combined with the diarylheptanoid compound or a pharmaceutically acceptable salt thereof. The EGFR-TKIs can be osimertinib, gefitinib, erlotinib or afatinib.
The lung cancer treated by the pharmaceutical composition of the present disclosure can be non-small cell lung cancer (NSCLC). In addition, the lung cancer can be resistant to the EGFR-TKIs.
Unless otherwise noted, all terms, symbols or other scientific terms or terms used in the present disclosure have the meanings that are commonly understood by person having ordinary skill in the art. In some cases, terms with conventional meanings
Rc Rc I , Re Re Formula (I), wherein Ra, Rb, Rai and RID' are independently H, C1-C2 alkyl, C1-C3 alkoxy, OH, or -0C(=0)Rd, wherein Rd is C1-C3 alkyl or C1-C3 alkanol; Rc is H, C1-C2 alkyl, .. C3-C6 unsaturated alkyl or C7-C12 arylalkyl with double or triple bonds;
and Re and Re' are independently H, C1-C6 alkyl or C1-C6 alkoxy.
At least one of Ra, Rb, Rai, and RID' of the diarylheptanoid compound of the present disclosure can be -0C(=0)Rd, and Rd is C1-C3 alkyl or C1-C3 alkanol. In addition, the diarylheptanoid compound can be interconvertible between keto and enol forms, when Rc is H.
The pharmaceutical composition of the present disclosure can further include epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs), which can be combined with the diarylheptanoid compound or a pharmaceutically acceptable salt thereof. The EGFR-TKIs can be osimertinib, gefitinib, erlotinib or afatinib.
The lung cancer treated by the pharmaceutical composition of the present disclosure can be non-small cell lung cancer (NSCLC). In addition, the lung cancer can be resistant to the EGFR-TKIs.
Unless otherwise noted, all terms, symbols or other scientific terms or terms used in the present disclosure have the meanings that are commonly understood by person having ordinary skill in the art. In some cases, terms with conventional meanings
9 Date Regue/Date Received 2023-06-16 are defined herein for clarity and/or immediate reference, and the definitions incorporated herein should be construed as not necessarily substantial different from the conventional meanings in the art. Many of the techniques and procedures described or referenced herein are well known and routinely used by those skilled in the art. Where appropriate, unless otherwise stated, procedures for the use of commercially available kits and reagents are generally performed according to instructions and/or parameters defined by the manufacturer.
Unless contraindicated or noted otherwise, in these descriptions and throughout this specification, the terms "a" and "an" mean one or more (that is at least one).
Furthermore, genera are recited as shorthand for a recitation of all members of the genus; for example, the recitation of C1-C3 alkyl is shorthand for a recitation of all C1-C3 alkyls including methyl, ethyl, propyl, and isomers thereof.
The diarylheptanoid compounds disclosed in the present disclosure and the pharmaceutically acceptable salt thereof can be verified by in vitro experiments, which can inhibit the growth of the EGFR-TKIs resistant NSCLC cells. It can further be verified by in vivo experiments that the compound disclosed in the specification and/or at least one pharmaceutically acceptable salt thereof can be administered to animals suffering from EGFR-TKIs resistant lung cancer (such as mouse model), and can obtain therapeutic effects. A positive result in one or more tests is sufficient to demonstrate the actual utility of the tested compound and/or salt, and an appropriate dosage range and administration route for animals (such as humans) can be determined based on test results.
Date Recue/Date Received 2023-06-16 Useful pharmaceutical dosage forms for administering the diarylheptanoid compound of the present disclosure and the pharmaceutically acceptable salt thereof include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injections and oral suspensions. The dosage administered can depend on factors including the age of the subject, the health and weight of the subject, the extent of the disease, the type of concomitant treatment (if any), the frequency of treatment and the nature of the desired effect. Usually the daily dose of active ingredient may vary, for example from 0.1 to 2000 mg per day. For example, 10-500 mg one or more times per day can be effective to achieve the desired results.
The same dosage form can generally be used when the diarylheptanoid compounds of the present disclosure and pharmaceutically acceptable salt thereof are administered stepwise or in combination with at least one other therapeutic agent.
When drugs are administered in a physical combination, the dosage form and route of administration should be selected based on the compatibility of the combined drugs.
Therefore, "co-administration" in the specification should be understood to include the concomitant or sequential administration of at least two agents, or as a fixed-dose combination of at least two active ingredients.
The diarylheptanoid compound and the pharmaceutically acceptable salt thereof in the specification can be used as the active ingredient alone, or administered in combination with at least one second active ingredient, the second active ingredient can be selected from, for example, other active ingredients known to be useful in the treatment of patients with NSCLC, in particular the EGFR-TKIs.
Date Regue/Date Received 2023-06-16 The following specific examples are used to further illustrate the present disclosure, in order to benefit the person having ordinary skill in the art, and can fully utilize and practice the present disclosure without excessive interpretation.
These examples should not be regarded as limiting the scope of the present disclosure, but is used to illustrate how to implement the materials and methods of the present disclosure.
1. Structure of the diarylheptanoid compound of the present disclosure The diarylheptanoid compound of the present disclosure uses curcumin (CCM) as a guiding compound to design a curcuminoid diarylheptanoid compound, which has a structure represented by Formula (I):
Re R ' a R R
c Rbi Re Re Formula (I), Please refer to the following Table 1, which shows Ra, Rb, Ra', Rc, Re and Re' of examples of the diarylheptanoid compound of the present disclosure -Compound 1, Compound 21a, Compound 21b, Compound 22a, Compound 22b, Compound 23a, Compound 23b, Compound 24a, Compound 24b, Compound 25, Compound 26, Compound 27, Compound 31, Compound 33, Compound 35a, Compound 35c, Compound 35d, Compound 35e, Compound 36 and Compound 37.
Date Recue/Date Received 2023-06-16 Table 1 Compound Ra Ra' Rb RID' Rc Re, Re' 21a OCH3 OCH3 ¨0-8 cH3 ¨0-8 cH3 H H
OH OH
O -OH
21b OCH3 OCH3 ¨0-8 cH3 OH H H
-OH
22a OCH3 OCH3 ¨0-g Ic2H5 ¨0-6 c2H5 H H
OH -OH
22b OCH3 OCH3 0 () c2H5OH H -- H
LOH
O [OH 0 [OH
23a H H ¨0-8 cH3 ¨0-8 cH3 H -- H
OH OH
O [OH
23b H H ¨0-8 8H3 OH H H
OH
24a ¨0-8 -OH -OH
24b ¨0-8 cH, -OH
LOH
O [OH 0 [OH
26 0C2H5 0C2H5 0-8 cH3 ¨0-8 cH3 H H
OH OH
27 0C2H5 0C2H5 0-8 c2H5 ¨0-8 c2H5 H H
OH OH
31 C2 H5 C2 H5 ¨0- CH3 ¨0- CH3 H C2H5 -OH -OH
O [OH
33 OCH3 OCH3 ¨0-8 cH3 OH
Date Regue/Date Received 2023-06-16 35a OCH3 OCH3 -(3-C CH3 H
-OH -OH
35c OCH3 OCH3 -(3-c cH3 -0-c cH3 benzyl H
-OH -OH
35d OCH3 OCH3 -o-c cH3 -o-c cH3 p-ropargyl H
OH OH
35e OCH3 OCH3 -(3-c cH3 -0-c cH3 allyl H
-OH -OH
36 H H -o-c cH3 -o-c cH3 OH OH
37 -0-c cH, -o-c cH3 OCH3 OCH3 CH3 H
-OH OH
Structures of Compound 21a-((1E,3Z,6E)-3-hydroxy-5-oxohepta- 1,3,6-triene-1,7-diy1)bis(2-methoxy-4,1-phenylene)bis(3-hydroxy-2-hydroxymethyl)-2-methylpropanoate, Compound 35a-((1E,6E)-4,4-dimethyl-3,5-dioxohepta-1, 6-diene-1,7-diy1)bis(2-methoxy-4,1-phenylene)bis(3-hydroxy-2-hydroxymethyl)-2-methylpropanoate, Compound 35d-((1E,6E)-3,5-dioxo-4,4-di(prop-2-yn-1-y1) hepta-1,6-diene-1,7-diy1)bis(2-methoxy-4,1-phenylene)bis(3-hydroxy-2-(hydroxymethyl)-methylpropanoate), Compound 36-((1E,6E)-4,4-dimethy1-3,5- dioxohepta-1,6-diene-1,7-diy1)bis(4,1-phenylene)bis(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate), and Corn pound 37-((1E,6E)-4,4-dimethy1-3,5- dioxohepta-1,6-dien-1,7-diy1)bis(2-io methoxy-5,1-phenylene)bis(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) are shown in Table 2.
Date Recue/Date Received 2023-06-16 Table 2 Compound Structure = OH
IVI ee0 " r, OM
21a HO 0== OH
OH
= 0 Me0 416 OlVie 35a HO"->ji0 411111)1P 0 OH
HO OH
I
35d HO"--)L0 36 He>fk0 0/11-eli HO OH
gir HO"->f0 OH
*INCOH IHO
The structure of Compound 21a includes a heptadiene-3,5-dione moiety, which can be readily interconvertible between the keto form and enol form. The 3- or OH group of the enol form combines with the adjacent 5- or 3-C=0 through hydrogen bonds to stabilize the structure thereof. In the present disclosure, two methyl functionalities are incorporated onto the 4-position of Compound 21a and afforded ((1E,6E)-4,4-dimethy1-3,5-dioxohepta-1,6-diene-1,7-diy1)bis(2-methoxy-4,1-phenylene)bis(3-hydroxy-2-hydroxymethyl)-2-methylpropanoate (35a), which is found to possess stable keto form, and is not able to tautomerization. In addition, in Date Recue/Date Received 2023-06-16 the present disclosure, Compound 35a is used as a new lead compound and derived into a series of 4,4-dialkyl derivatives thereof (Compound 35a, Compound 35d, Compound 36 and Compound 37) with stable keto form.
2. Inhibitory growth effect of the diarylheptanoid compound of the present disclosure on the EGFR gene mutant NSCLC cells and the EGFR-TKIs resistant NSCLC cells The EGFR gene mutant NSCLC cells were treated with the diarylheptanoid compounds of the present disclosure, and then the cell survival was stained with crystal violet to measure the IC50 values of the diarylheptanoid compounds of the present disclosure in the EGFR gene mutant NSCLC cells, so as to determine the growth inhibitory effect of the diarylheptanoid compounds of the present disclosure on the EGFR gene mutant NSCLC cells.
EGFR gene mutations in lung cancer are mostly found in exons 18-21, which are the intracellular tyrosine kinase coding region. The most common mutations include E746-A750del in exon 19 and L858R point mutation in exon 21, which account for about 85%-90% of EGFR gene mutations. Tumor cells with these two mutations are sensitive to the EGFR-TKIs, known as activating mutations. Secondary mutations may occur in some tumor cells, and the most common secondary mutation is the T790M mutation in exon 20, which is a drug resistance mutation. Please refer to Fig. 1A, which shows the analysis result of the inhibition of the H1650 cells growth by the diarylheptanoid compounds of the present disclosure. The H1650 cells have the E746-A750del mutation in exon 19 of the EGFR gene, wherein the CCM represents curcumin and the BDMC represents bisdemethoxycurcumin. The IC50 value of the Date Recue/Date Received 2023-06-16 compound > 16 pM shows that the H1650 cells have not yet reached 50% cell growth inhibition after treatment with compounds at concentrations as high as 16 pM, and data in Fig. 1A are represented by mean SD (n = 3).
Fig. 1A shows the IC50 values in the H1650 cells treated with 22 diarylheptanoid compounds (including BDMC) and curcumin for 3 days. 18 diarylheptanoid compounds including Compound 1, Compound 24b, Compound 23b, Compound 33, Compound 25, Compound 35b, Compound 22a, Compound 21a, Compound 22b, Compound 26, Compound 36, Compound 35a, Compound 35c, Compound 27, Compound 31, Compound 37, Compound 35e and Compound 35d have significantly io better inhibitory activity than the parent compound - curcumin on the growth of the H1650 cells, wherein ** represents p <0.05, *** represents p <0.01, ****
represents p <0.001.
Experimentally, another 7 EGFR-TKIs resistant NSCLC cells were treated with Compound 21a, Compound 35a, Compound 35d, Compound 36 or Compound 37, and then the cell survival assay was performed to measure the IC50 values of the diarylheptanoid compounds of the present disclosure in the EGFR-TKIs resistant NSCLC cells, so as to determine the growth inhibitory effect of the diarylheptanoid compounds of the present disclosure on the EGFR-TKIs resistant NSCLC cells.
The EGFR-TKIs resistant NSCLC cells used in the test include the H1975 cells, the cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells, in which the H1975 cells have a point mutation of L858R in exon 21 and a secondary mutation of T790M in exon 20; the GR2 cells, the GR5 cells, the GR6 cells, the cells, the GR9 cells and the GR10 cells are gefitinib-resistant cell lines obtained after Date Recue/Date Received 2023-06-16 treating gefitinib with the HCC827 cells as parental cells, while the HCC827 cells and the H1650 cells are the NSCLC cells with E746-A750del mutation of EGFR exon 19.
Please refer to Fig. 1B, Fig. 1C and Fig. 1D. Fig. 1B shows the analysis result of the inhibition of the H1975 cells growth by the diarylheptanoid compounds of the present disclosure. Fig. 1C shows the analysis result of the inhibition of the cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells growth by the diarylheptanoid compounds of the present disclosure. Fig. 1D
shows the percentage changes of the IC50 values after the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells were treated with Compound 35d and gefitinib respectively. Data in Fig. 1B and Fig. 1C are presented as mean SD (n = 3), while the IC50 value > 16 pM show that the test cells have not yet reached 50% cell growth inhibition after treatment with compounds at concentrations as high as 16 pM. Gef in Fig. 1D represents gefitinib.
Fig. 1B shows the measured the IC50 values of the H1975 cells treated with Compound 21a, Compound 35a, Compound 35d, Compound 36, Compound 37 and curcumin for 3 days, respectively. The results showed that Compound 21a, Compound 35a, Compound 35d, Compound 36 and Compound 37 of the present disclosure had significantly better inhibitory activity than curcumin on the growth of the H1975 cells.
Fig. 1C shows the measured the IC50 values of the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells after treatment with Compound 21a, Compound 35a, Compound 35d, Compound 36, Compound 37 and curcumin for 3 days, respectively.
The results show that Compound 21a, Date Recue/Date Received 2023-06-16 Compound 35a, Compound 35d, Compound 36 and Compound 37 of the present disclosure have significantly better inhibitory activity than curcumin on the growth of the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells.
The results in Fig. 1B and Fig. 1C show that all EGFR-TKIs resistant NSCLC
cells are more sensitive to Compound 21a, Compound 35a, Compound 35d, Compound 36 and Compound 37 than curcumin, and can achieve 50% inhibition of cell growth at significantly lower concentrations.
Fig. 1D shows that the analysis results obtained by comparing the IC50 values io measured by the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells with the IC50 value measured by the HCC827 cells, in which the HCC827 cells, the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells were treated with Compound 35d and gefitinib for days and then measured the IC50 values. The results in Fig. 1D show that all is gefitinib-resistant cell lines are indirectly sensitive to Compound 35d.
All gefitinib-resistant cell lines were >200-fold more resistant to gefitinib (Gef) than their parental cells, the HCC827 cells.
3. Anticancer activity of Compound 35d against the GR6 tumor, the GR8 tumor and the HCC827 tumor 20 In order to verify the anticancer effect of the diarylheptanoid compound of the present disclosure in vivo, the GR6 tumor mouse model, the GR8 tumor mouse model and the HCC827 tumor mouse model of xenotransplantation were first established, and the GR6 tumor mice, the GR8 tumor mice, and the HCC827 tumor mice were Date Regue/Date Received 2023-06-16 treated with 100 mg/kg of Compound 35d daily for 35 days, and the tumor size and body weight of the GR6 tumor mice, the GR8 tumor mice, and the HCC827 tumor mice were recorded.
Please refer to Fig. 2A to Fig. 2D, Fig. 2A shows the analysis result of the inhibition of tumor growth in the GR6 tumor mice by treating Compound 35d alone, Fig. 2B shows the analysis result of the inhibition of tumor growth in the GR8 tumor mice by treating Compound 35d alone, Fig. 2C shows the analysis result of the inhibition of tumor growth in the HCC827 tumor mice by treating Compound 35d alone, and Fig. 2D shows the statistical chart of body weight changes in the tumor mice by io treating Compound 35d alone, wherein data in Fig. 2A to Fig. 2C are presented as mean SEM (n = 10).
The results in Fig. 2A to Fig. 2C show that Compound 35d significantly inhibits the tumor growth of the GR6 tumor mice and the GR8 tumor mice, but has less significant effect on inhibiting the tumor growth of the HCC827 tumor mice.
However, the results in Fig. 2D show that the body weight of the tumor mice did not decrease significantly after being treated with Compound 35d for more than 1 month.
4. Combined treatment of Compound 35d and osimertinib inhibits the re-progression of the GR6 tumor EGFR-TKIs are currently the standard treatment for NSCLC patients with the EGFR gene mutation. To further test whether the combined use of the diarylheptanoid compound of the present disclosure and known ones can enhance the therapeutic effect of NSCLC, the GR6 tumor mice were divided into 4 groups.
One group received 100 mg/kg Compound 35d treatment per day (represented as Date Recue/Date Received 2023-06-16 35d), another group received 1 mg/kg osimertinib treatment per day (represented as Osi), still another group received the combined treatment of 100 mg/kg Compound 35d and 1 mg/kg osimertinib per day (represented as 35d+Osi), and the other group was the control group without drug treatment.
Please refer to Fig. 3A and Fig. 3B, Fig. 3A shows the analysis result of the inhibition of tumor re-progression in the GR6 tumor mice by treating the combined treatment of Compound 35d and osimertinib, and Fig. 3B shows the statistical chart of body weight changes in the GR6 tumor mice by treating the combined treatment of Compound 35d and osimertinib, wherein data in Fig. 3A and Fig. 3B are .. represented by mean SEM (n = 10).
The results in Fig. 3A show that although the tumor size of the GR6 tumor mice in the Osi group was initially reduced by osimertinib treatment, the treated tumors subsequently re-growth, indicating that the tumors of the GR6 tumor mice have EGFR-TKIs resistance. However, no matter in the group treated with Compound 35d alone or in the group treated with the combined treatment of Compound 35d and osimertinib, tumor re-progression in the GR6 tumor mice was significantly inhibited.
And the results in Fig. 3B show that neither the single treatment of Compound 35d nor the combined treatment of Compound 35d and osimertinib can significantly reduce the body weight of mice.
To sum up, the present disclosure provides a new use of the pharmaceutical composition, which can be used to manufacture a drug for treating lung cancer.
The pharmaceutical composition includes the diarylheptanoid compound or the pharmaceutically acceptable salt thereof, which can inhibit the growth of the EGFR
Date Recue/Date Received 2023-06-16 gene mutant NSCLC cells and the EGFR-TKIs resistant NSCLC cells, so that can be used to manufacture the drug for treating lung cancer.
Moreover, the pharmaceutical composition can have a synergistic effect when used in combination with EGFR-TKIs, which can increase the effectiveness of treating lung cancer, especially for the treatment of lung cancer with the EGFR gene mutation and EGFR-TKIs, and has the potential to be used in the medical and health care market.
Although the present disclosure has been described as above by way of embodiments, it is not intended to limit the present disclosure. Person having skilled in the art can make various changes and modifications without departing from the spirit and scope of the present disclosure. Therefore, the scope of protection of the present disclosure should be defined by the scope of the appended patent application.
Date Recue/Date Received 2023-06-16
Unless contraindicated or noted otherwise, in these descriptions and throughout this specification, the terms "a" and "an" mean one or more (that is at least one).
Furthermore, genera are recited as shorthand for a recitation of all members of the genus; for example, the recitation of C1-C3 alkyl is shorthand for a recitation of all C1-C3 alkyls including methyl, ethyl, propyl, and isomers thereof.
The diarylheptanoid compounds disclosed in the present disclosure and the pharmaceutically acceptable salt thereof can be verified by in vitro experiments, which can inhibit the growth of the EGFR-TKIs resistant NSCLC cells. It can further be verified by in vivo experiments that the compound disclosed in the specification and/or at least one pharmaceutically acceptable salt thereof can be administered to animals suffering from EGFR-TKIs resistant lung cancer (such as mouse model), and can obtain therapeutic effects. A positive result in one or more tests is sufficient to demonstrate the actual utility of the tested compound and/or salt, and an appropriate dosage range and administration route for animals (such as humans) can be determined based on test results.
Date Recue/Date Received 2023-06-16 Useful pharmaceutical dosage forms for administering the diarylheptanoid compound of the present disclosure and the pharmaceutically acceptable salt thereof include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injections and oral suspensions. The dosage administered can depend on factors including the age of the subject, the health and weight of the subject, the extent of the disease, the type of concomitant treatment (if any), the frequency of treatment and the nature of the desired effect. Usually the daily dose of active ingredient may vary, for example from 0.1 to 2000 mg per day. For example, 10-500 mg one or more times per day can be effective to achieve the desired results.
The same dosage form can generally be used when the diarylheptanoid compounds of the present disclosure and pharmaceutically acceptable salt thereof are administered stepwise or in combination with at least one other therapeutic agent.
When drugs are administered in a physical combination, the dosage form and route of administration should be selected based on the compatibility of the combined drugs.
Therefore, "co-administration" in the specification should be understood to include the concomitant or sequential administration of at least two agents, or as a fixed-dose combination of at least two active ingredients.
The diarylheptanoid compound and the pharmaceutically acceptable salt thereof in the specification can be used as the active ingredient alone, or administered in combination with at least one second active ingredient, the second active ingredient can be selected from, for example, other active ingredients known to be useful in the treatment of patients with NSCLC, in particular the EGFR-TKIs.
Date Regue/Date Received 2023-06-16 The following specific examples are used to further illustrate the present disclosure, in order to benefit the person having ordinary skill in the art, and can fully utilize and practice the present disclosure without excessive interpretation.
These examples should not be regarded as limiting the scope of the present disclosure, but is used to illustrate how to implement the materials and methods of the present disclosure.
1. Structure of the diarylheptanoid compound of the present disclosure The diarylheptanoid compound of the present disclosure uses curcumin (CCM) as a guiding compound to design a curcuminoid diarylheptanoid compound, which has a structure represented by Formula (I):
Re R ' a R R
c Rbi Re Re Formula (I), Please refer to the following Table 1, which shows Ra, Rb, Ra', Rc, Re and Re' of examples of the diarylheptanoid compound of the present disclosure -Compound 1, Compound 21a, Compound 21b, Compound 22a, Compound 22b, Compound 23a, Compound 23b, Compound 24a, Compound 24b, Compound 25, Compound 26, Compound 27, Compound 31, Compound 33, Compound 35a, Compound 35c, Compound 35d, Compound 35e, Compound 36 and Compound 37.
Date Recue/Date Received 2023-06-16 Table 1 Compound Ra Ra' Rb RID' Rc Re, Re' 21a OCH3 OCH3 ¨0-8 cH3 ¨0-8 cH3 H H
OH OH
O -OH
21b OCH3 OCH3 ¨0-8 cH3 OH H H
-OH
22a OCH3 OCH3 ¨0-g Ic2H5 ¨0-6 c2H5 H H
OH -OH
22b OCH3 OCH3 0 () c2H5OH H -- H
LOH
O [OH 0 [OH
23a H H ¨0-8 cH3 ¨0-8 cH3 H -- H
OH OH
O [OH
23b H H ¨0-8 8H3 OH H H
OH
24a ¨0-8 -OH -OH
24b ¨0-8 cH, -OH
LOH
O [OH 0 [OH
26 0C2H5 0C2H5 0-8 cH3 ¨0-8 cH3 H H
OH OH
27 0C2H5 0C2H5 0-8 c2H5 ¨0-8 c2H5 H H
OH OH
31 C2 H5 C2 H5 ¨0- CH3 ¨0- CH3 H C2H5 -OH -OH
O [OH
33 OCH3 OCH3 ¨0-8 cH3 OH
Date Regue/Date Received 2023-06-16 35a OCH3 OCH3 -(3-C CH3 H
-OH -OH
35c OCH3 OCH3 -(3-c cH3 -0-c cH3 benzyl H
-OH -OH
35d OCH3 OCH3 -o-c cH3 -o-c cH3 p-ropargyl H
OH OH
35e OCH3 OCH3 -(3-c cH3 -0-c cH3 allyl H
-OH -OH
36 H H -o-c cH3 -o-c cH3 OH OH
37 -0-c cH, -o-c cH3 OCH3 OCH3 CH3 H
-OH OH
Structures of Compound 21a-((1E,3Z,6E)-3-hydroxy-5-oxohepta- 1,3,6-triene-1,7-diy1)bis(2-methoxy-4,1-phenylene)bis(3-hydroxy-2-hydroxymethyl)-2-methylpropanoate, Compound 35a-((1E,6E)-4,4-dimethyl-3,5-dioxohepta-1, 6-diene-1,7-diy1)bis(2-methoxy-4,1-phenylene)bis(3-hydroxy-2-hydroxymethyl)-2-methylpropanoate, Compound 35d-((1E,6E)-3,5-dioxo-4,4-di(prop-2-yn-1-y1) hepta-1,6-diene-1,7-diy1)bis(2-methoxy-4,1-phenylene)bis(3-hydroxy-2-(hydroxymethyl)-methylpropanoate), Compound 36-((1E,6E)-4,4-dimethy1-3,5- dioxohepta-1,6-diene-1,7-diy1)bis(4,1-phenylene)bis(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate), and Corn pound 37-((1E,6E)-4,4-dimethy1-3,5- dioxohepta-1,6-dien-1,7-diy1)bis(2-io methoxy-5,1-phenylene)bis(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) are shown in Table 2.
Date Recue/Date Received 2023-06-16 Table 2 Compound Structure = OH
IVI ee0 " r, OM
21a HO 0== OH
OH
= 0 Me0 416 OlVie 35a HO"->ji0 411111)1P 0 OH
HO OH
I
35d HO"--)L0 36 He>fk0 0/11-eli HO OH
gir HO"->f0 OH
*INCOH IHO
The structure of Compound 21a includes a heptadiene-3,5-dione moiety, which can be readily interconvertible between the keto form and enol form. The 3- or OH group of the enol form combines with the adjacent 5- or 3-C=0 through hydrogen bonds to stabilize the structure thereof. In the present disclosure, two methyl functionalities are incorporated onto the 4-position of Compound 21a and afforded ((1E,6E)-4,4-dimethy1-3,5-dioxohepta-1,6-diene-1,7-diy1)bis(2-methoxy-4,1-phenylene)bis(3-hydroxy-2-hydroxymethyl)-2-methylpropanoate (35a), which is found to possess stable keto form, and is not able to tautomerization. In addition, in Date Recue/Date Received 2023-06-16 the present disclosure, Compound 35a is used as a new lead compound and derived into a series of 4,4-dialkyl derivatives thereof (Compound 35a, Compound 35d, Compound 36 and Compound 37) with stable keto form.
2. Inhibitory growth effect of the diarylheptanoid compound of the present disclosure on the EGFR gene mutant NSCLC cells and the EGFR-TKIs resistant NSCLC cells The EGFR gene mutant NSCLC cells were treated with the diarylheptanoid compounds of the present disclosure, and then the cell survival was stained with crystal violet to measure the IC50 values of the diarylheptanoid compounds of the present disclosure in the EGFR gene mutant NSCLC cells, so as to determine the growth inhibitory effect of the diarylheptanoid compounds of the present disclosure on the EGFR gene mutant NSCLC cells.
EGFR gene mutations in lung cancer are mostly found in exons 18-21, which are the intracellular tyrosine kinase coding region. The most common mutations include E746-A750del in exon 19 and L858R point mutation in exon 21, which account for about 85%-90% of EGFR gene mutations. Tumor cells with these two mutations are sensitive to the EGFR-TKIs, known as activating mutations. Secondary mutations may occur in some tumor cells, and the most common secondary mutation is the T790M mutation in exon 20, which is a drug resistance mutation. Please refer to Fig. 1A, which shows the analysis result of the inhibition of the H1650 cells growth by the diarylheptanoid compounds of the present disclosure. The H1650 cells have the E746-A750del mutation in exon 19 of the EGFR gene, wherein the CCM represents curcumin and the BDMC represents bisdemethoxycurcumin. The IC50 value of the Date Recue/Date Received 2023-06-16 compound > 16 pM shows that the H1650 cells have not yet reached 50% cell growth inhibition after treatment with compounds at concentrations as high as 16 pM, and data in Fig. 1A are represented by mean SD (n = 3).
Fig. 1A shows the IC50 values in the H1650 cells treated with 22 diarylheptanoid compounds (including BDMC) and curcumin for 3 days. 18 diarylheptanoid compounds including Compound 1, Compound 24b, Compound 23b, Compound 33, Compound 25, Compound 35b, Compound 22a, Compound 21a, Compound 22b, Compound 26, Compound 36, Compound 35a, Compound 35c, Compound 27, Compound 31, Compound 37, Compound 35e and Compound 35d have significantly io better inhibitory activity than the parent compound - curcumin on the growth of the H1650 cells, wherein ** represents p <0.05, *** represents p <0.01, ****
represents p <0.001.
Experimentally, another 7 EGFR-TKIs resistant NSCLC cells were treated with Compound 21a, Compound 35a, Compound 35d, Compound 36 or Compound 37, and then the cell survival assay was performed to measure the IC50 values of the diarylheptanoid compounds of the present disclosure in the EGFR-TKIs resistant NSCLC cells, so as to determine the growth inhibitory effect of the diarylheptanoid compounds of the present disclosure on the EGFR-TKIs resistant NSCLC cells.
The EGFR-TKIs resistant NSCLC cells used in the test include the H1975 cells, the cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells, in which the H1975 cells have a point mutation of L858R in exon 21 and a secondary mutation of T790M in exon 20; the GR2 cells, the GR5 cells, the GR6 cells, the cells, the GR9 cells and the GR10 cells are gefitinib-resistant cell lines obtained after Date Recue/Date Received 2023-06-16 treating gefitinib with the HCC827 cells as parental cells, while the HCC827 cells and the H1650 cells are the NSCLC cells with E746-A750del mutation of EGFR exon 19.
Please refer to Fig. 1B, Fig. 1C and Fig. 1D. Fig. 1B shows the analysis result of the inhibition of the H1975 cells growth by the diarylheptanoid compounds of the present disclosure. Fig. 1C shows the analysis result of the inhibition of the cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells growth by the diarylheptanoid compounds of the present disclosure. Fig. 1D
shows the percentage changes of the IC50 values after the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells were treated with Compound 35d and gefitinib respectively. Data in Fig. 1B and Fig. 1C are presented as mean SD (n = 3), while the IC50 value > 16 pM show that the test cells have not yet reached 50% cell growth inhibition after treatment with compounds at concentrations as high as 16 pM. Gef in Fig. 1D represents gefitinib.
Fig. 1B shows the measured the IC50 values of the H1975 cells treated with Compound 21a, Compound 35a, Compound 35d, Compound 36, Compound 37 and curcumin for 3 days, respectively. The results showed that Compound 21a, Compound 35a, Compound 35d, Compound 36 and Compound 37 of the present disclosure had significantly better inhibitory activity than curcumin on the growth of the H1975 cells.
Fig. 1C shows the measured the IC50 values of the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells after treatment with Compound 21a, Compound 35a, Compound 35d, Compound 36, Compound 37 and curcumin for 3 days, respectively.
The results show that Compound 21a, Date Recue/Date Received 2023-06-16 Compound 35a, Compound 35d, Compound 36 and Compound 37 of the present disclosure have significantly better inhibitory activity than curcumin on the growth of the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells.
The results in Fig. 1B and Fig. 1C show that all EGFR-TKIs resistant NSCLC
cells are more sensitive to Compound 21a, Compound 35a, Compound 35d, Compound 36 and Compound 37 than curcumin, and can achieve 50% inhibition of cell growth at significantly lower concentrations.
Fig. 1D shows that the analysis results obtained by comparing the IC50 values io measured by the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells with the IC50 value measured by the HCC827 cells, in which the HCC827 cells, the GR2 cells, the GR5 cells, the GR6 cells, the GR8 cells, the GR9 cells and the GR10 cells were treated with Compound 35d and gefitinib for days and then measured the IC50 values. The results in Fig. 1D show that all is gefitinib-resistant cell lines are indirectly sensitive to Compound 35d.
All gefitinib-resistant cell lines were >200-fold more resistant to gefitinib (Gef) than their parental cells, the HCC827 cells.
3. Anticancer activity of Compound 35d against the GR6 tumor, the GR8 tumor and the HCC827 tumor 20 In order to verify the anticancer effect of the diarylheptanoid compound of the present disclosure in vivo, the GR6 tumor mouse model, the GR8 tumor mouse model and the HCC827 tumor mouse model of xenotransplantation were first established, and the GR6 tumor mice, the GR8 tumor mice, and the HCC827 tumor mice were Date Regue/Date Received 2023-06-16 treated with 100 mg/kg of Compound 35d daily for 35 days, and the tumor size and body weight of the GR6 tumor mice, the GR8 tumor mice, and the HCC827 tumor mice were recorded.
Please refer to Fig. 2A to Fig. 2D, Fig. 2A shows the analysis result of the inhibition of tumor growth in the GR6 tumor mice by treating Compound 35d alone, Fig. 2B shows the analysis result of the inhibition of tumor growth in the GR8 tumor mice by treating Compound 35d alone, Fig. 2C shows the analysis result of the inhibition of tumor growth in the HCC827 tumor mice by treating Compound 35d alone, and Fig. 2D shows the statistical chart of body weight changes in the tumor mice by io treating Compound 35d alone, wherein data in Fig. 2A to Fig. 2C are presented as mean SEM (n = 10).
The results in Fig. 2A to Fig. 2C show that Compound 35d significantly inhibits the tumor growth of the GR6 tumor mice and the GR8 tumor mice, but has less significant effect on inhibiting the tumor growth of the HCC827 tumor mice.
However, the results in Fig. 2D show that the body weight of the tumor mice did not decrease significantly after being treated with Compound 35d for more than 1 month.
4. Combined treatment of Compound 35d and osimertinib inhibits the re-progression of the GR6 tumor EGFR-TKIs are currently the standard treatment for NSCLC patients with the EGFR gene mutation. To further test whether the combined use of the diarylheptanoid compound of the present disclosure and known ones can enhance the therapeutic effect of NSCLC, the GR6 tumor mice were divided into 4 groups.
One group received 100 mg/kg Compound 35d treatment per day (represented as Date Recue/Date Received 2023-06-16 35d), another group received 1 mg/kg osimertinib treatment per day (represented as Osi), still another group received the combined treatment of 100 mg/kg Compound 35d and 1 mg/kg osimertinib per day (represented as 35d+Osi), and the other group was the control group without drug treatment.
Please refer to Fig. 3A and Fig. 3B, Fig. 3A shows the analysis result of the inhibition of tumor re-progression in the GR6 tumor mice by treating the combined treatment of Compound 35d and osimertinib, and Fig. 3B shows the statistical chart of body weight changes in the GR6 tumor mice by treating the combined treatment of Compound 35d and osimertinib, wherein data in Fig. 3A and Fig. 3B are .. represented by mean SEM (n = 10).
The results in Fig. 3A show that although the tumor size of the GR6 tumor mice in the Osi group was initially reduced by osimertinib treatment, the treated tumors subsequently re-growth, indicating that the tumors of the GR6 tumor mice have EGFR-TKIs resistance. However, no matter in the group treated with Compound 35d alone or in the group treated with the combined treatment of Compound 35d and osimertinib, tumor re-progression in the GR6 tumor mice was significantly inhibited.
And the results in Fig. 3B show that neither the single treatment of Compound 35d nor the combined treatment of Compound 35d and osimertinib can significantly reduce the body weight of mice.
To sum up, the present disclosure provides a new use of the pharmaceutical composition, which can be used to manufacture a drug for treating lung cancer.
The pharmaceutical composition includes the diarylheptanoid compound or the pharmaceutically acceptable salt thereof, which can inhibit the growth of the EGFR
Date Recue/Date Received 2023-06-16 gene mutant NSCLC cells and the EGFR-TKIs resistant NSCLC cells, so that can be used to manufacture the drug for treating lung cancer.
Moreover, the pharmaceutical composition can have a synergistic effect when used in combination with EGFR-TKIs, which can increase the effectiveness of treating lung cancer, especially for the treatment of lung cancer with the EGFR gene mutation and EGFR-TKIs, and has the potential to be used in the medical and health care market.
Although the present disclosure has been described as above by way of embodiments, it is not intended to limit the present disclosure. Person having skilled in the art can make various changes and modifications without departing from the spirit and scope of the present disclosure. Therefore, the scope of protection of the present disclosure should be defined by the scope of the appended patent application.
Date Recue/Date Received 2023-06-16
Claims (10)
1. A use of a pharmaceutical composition, characterized in that, the pharmaceutical composition is used to manufacture a drug for treating a lung cancer, wherein the pharmaceutical composition comprises a diarylheptanoid compound or a pharmaceutically acceptable salt thereof, the diarylheptanoid compound has a structure represented by Formula (l):
Ra R
a Rb RC RC
Rbi Re Re Formula (l), wherein Ra, Rb, Ra' and Rb' are independently H, C1-C2 alkyl, C1-C3 alkoxy, OH, or -0C(=0)Rd, wherein Rd is C1-C3 alkyl or Cl-C3 alkanol; Rc is H, C1-C2 alkyl, C3-C6 unsaturated alkyl or C7-C12 arylalkyl with double or triple bonds; and Re and Re' are independently H, C1-C6 alkyl or C1-C6 alkoxy.
Ra R
a Rb RC RC
Rbi Re Re Formula (l), wherein Ra, Rb, Ra' and Rb' are independently H, C1-C2 alkyl, C1-C3 alkoxy, OH, or -0C(=0)Rd, wherein Rd is C1-C3 alkyl or Cl-C3 alkanol; Rc is H, C1-C2 alkyl, C3-C6 unsaturated alkyl or C7-C12 arylalkyl with double or triple bonds; and Re and Re' are independently H, C1-C6 alkyl or C1-C6 alkoxy.
2. The use of the pharmaceutical composition of claim 1, wherein at least one of Ra, Rh, Ra', and Rb' is -0C(=0)Rd, wherein Rd is C1-C3 alkyl or C1-C3 alkanol.
3. The use of the pharmaceutical composition of claim 1, wherein the diarylheptanoid compound is interconvertible between keto form and enol form, when Rc is H.
Date Recue/Date Received 2023-06-16
Date Recue/Date Received 2023-06-16
4. The use of the pharmaceutical composition of claim 1, wherein the diarylheptanoid compound is selected from Compound 1, Compound 21a, Compound 21b, Compound 22a, Compound 22b, Compound 23a, Compound 23b, Compound 24a, Compound 24b, Compound 25, Compound 26, Compound 27, Compound 31 and Compound 33 having a structure represented by Formula (II):
R1 --" R1' Formula (II);
wherein Ri, Ri' are OCH3 respectively, R2, R2' are H respectively, R3, R3' are H respectively in Compound 1; Ri, Ri' are OCH3 respectively, R2, R2' are 0R4 respectively, R3, R3' are H respectively in Compound 21a; Ri, Ri' are OCH3 respectively, R2 iS OH, R2' iS 0R4, R3, R3' are H respectively in Compound 21b; Ri, Ri' are OCH3 respectively, R2, R2' are 0R5 respectively, R3, R3' are H
respectively in Compound 22a; Ri, Ri' are OCH3 respectively, R2 iS OH, R2' is OR5, R3, R3' are H
respectively in Compound 22b; Ri, Ri' are H respectively, R2, R2' are ORs respectively, R3, R3' are H respectively in Compound 23a; Ri, Ri' are H
respectively, R2 iS OR5, R2' iS OH, R3, R3' are H respectively in Compound 23b; Ri, Ri' are respectively, R2, R2' are OCH3 respectively, R3, R3' are H respectively in Compound 24a; Ri is 0R4, Ri' is OH, R2, R2' are OCH3 respectively, R3, R3' are H
respectively in Compound 24b; Ri is ORs, Ri' is OH, R2, R2' are OCH3 respectively, R3, R3' are H
Date Recue/Date Received 2023-06-16 respectively in Compound 25; Ri, Ri' are 0C2H5 respectively, R2, R2' are 0R4 respectively, R3, R3' are H respectively in Compound 26; Ri, Ri' are 0C2H5 respectively, R2, R2' are OR5 respectively, R3, R3' are H respectively in Compound 27;
Ri, Ri' are C2H5 respectively, R2, R2' are OR5 respectively, R3, R3' are C2H5 respectively in Compound 31; and Ri, Ri' are OCH3 respectively, R2 is OCH3, R2' iS
0R4, R3, R3' are H respectively in Compound 33;
wherein R4 is a structure represented by Formula (i), and R5 is a structure represented by Formula (ii):
ÇOH
VrOH
OH OH
Formula (i); Formula (ii).
R1 --" R1' Formula (II);
wherein Ri, Ri' are OCH3 respectively, R2, R2' are H respectively, R3, R3' are H respectively in Compound 1; Ri, Ri' are OCH3 respectively, R2, R2' are 0R4 respectively, R3, R3' are H respectively in Compound 21a; Ri, Ri' are OCH3 respectively, R2 iS OH, R2' iS 0R4, R3, R3' are H respectively in Compound 21b; Ri, Ri' are OCH3 respectively, R2, R2' are 0R5 respectively, R3, R3' are H
respectively in Compound 22a; Ri, Ri' are OCH3 respectively, R2 iS OH, R2' is OR5, R3, R3' are H
respectively in Compound 22b; Ri, Ri' are H respectively, R2, R2' are ORs respectively, R3, R3' are H respectively in Compound 23a; Ri, Ri' are H
respectively, R2 iS OR5, R2' iS OH, R3, R3' are H respectively in Compound 23b; Ri, Ri' are respectively, R2, R2' are OCH3 respectively, R3, R3' are H respectively in Compound 24a; Ri is 0R4, Ri' is OH, R2, R2' are OCH3 respectively, R3, R3' are H
respectively in Compound 24b; Ri is ORs, Ri' is OH, R2, R2' are OCH3 respectively, R3, R3' are H
Date Recue/Date Received 2023-06-16 respectively in Compound 25; Ri, Ri' are 0C2H5 respectively, R2, R2' are 0R4 respectively, R3, R3' are H respectively in Compound 26; Ri, Ri' are 0C2H5 respectively, R2, R2' are OR5 respectively, R3, R3' are H respectively in Compound 27;
Ri, Ri' are C2H5 respectively, R2, R2' are OR5 respectively, R3, R3' are C2H5 respectively in Compound 31; and Ri, Ri' are OCH3 respectively, R2 is OCH3, R2' iS
0R4, R3, R3' are H respectively in Compound 33;
wherein R4 is a structure represented by Formula (i), and R5 is a structure represented by Formula (ii):
ÇOH
VrOH
OH OH
Formula (i); Formula (ii).
5. The use of the pharmaceutical composition of claim 1, wherein the diarylheptanoid compound is selected from Compound 35a, Compound 35c, Compound 35d, Compound 35e, Compound 36 and Compound 37 having a structure represented by Formula (III):
R6 ss.. R6' ix7 Formula (III);
Date Recue/Date Received 2023-06-16 wherein R6, R6' are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is CH3 in Compound 35a; R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is benzyl in Compound 35c; R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is propargyl in Compound 35d; R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is allyl in Compound 35e; R6, Re are H respectively, R7, R7' are 0R4 respectively, R8 is CH3 in Compound 36; and R6, Re are 0R4 respectively, R7, R7' are OCH3 respectively, R8 is CH3 in Compound 37;
wherein R4 is a structure represented by Formula (i):
ÇOH
Formula (i).
R6 ss.. R6' ix7 Formula (III);
Date Recue/Date Received 2023-06-16 wherein R6, R6' are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is CH3 in Compound 35a; R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is benzyl in Compound 35c; R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is propargyl in Compound 35d; R6, Re are OCH3 respectively, R7, R7' are 0R4 respectively, R8 is allyl in Compound 35e; R6, Re are H respectively, R7, R7' are 0R4 respectively, R8 is CH3 in Compound 36; and R6, Re are 0R4 respectively, R7, R7' are OCH3 respectively, R8 is CH3 in Compound 37;
wherein R4 is a structure represented by Formula (i):
ÇOH
Formula (i).
6.
The use of the pharmaceutical composition of claim 1, wherein the diarylheptanoid compound is selected from:
meoNja = 0 OH HO'>
HO
**"011.1 HO
= =
Me 0Me 0 0, ?CQH
I I
HO OH
and o 0 He>fil*'0 OH
HsCO OCH3 Date Recue/Date Received 2023-06-16
The use of the pharmaceutical composition of claim 1, wherein the diarylheptanoid compound is selected from:
meoNja = 0 OH HO'>
HO
**"011.1 HO
= =
Me 0Me 0 0, ?CQH
I I
HO OH
and o 0 He>fil*'0 OH
HsCO OCH3 Date Recue/Date Received 2023-06-16
7. The use of the pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKls).
8. The use of the pharmaceutical composition of claim 7, wherein the EGFR-TKls are osimertinib, gefitinib, erlotinib or afatinib.
9. The use of the pharmaceutical composition of claim 1, wherein the lung cancer is a non-small cell lung cancer.
10. The use of the pharmaceutical composition of claim 1, wherein the lung cancer is resistant to epidermal growth factor receptor-tyrosine kinase inhibitors.
Date Regue/Date Received 2023-06-16
Date Regue/Date Received 2023-06-16
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063126849P | 2020-12-17 | 2020-12-17 | |
US63/126,849 | 2020-12-17 | ||
PCT/CN2021/137647 WO2022127751A1 (en) | 2020-12-17 | 2021-12-14 | Use of pharmaceutical composition for treating lung cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3205490A1 true CA3205490A1 (en) | 2022-06-23 |
Family
ID=82060052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3205490A Pending CA3205490A1 (en) | 2020-12-17 | 2021-12-14 | Use of pharmaceutical composition for treating lung cancer |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240000742A1 (en) |
EP (1) | EP4265256A4 (en) |
JP (1) | JP2023554532A (en) |
KR (1) | KR20230131861A (en) |
CN (1) | CN117120438A (en) |
AU (1) | AU2021402788A1 (en) |
CA (1) | CA3205490A1 (en) |
TW (1) | TWI798994B (en) |
WO (1) | WO2022127751A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI405566B (en) * | 2010-02-11 | 2013-08-21 | Univ Nat Taiwan | Use of curcumin or its analogues in cancer therapy utilizing epidermal growth factor receptor tyrosine kinase inhibitor |
WO2016181220A2 (en) * | 2015-05-13 | 2016-11-17 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions and methods of use thereof |
CN105476996B (en) * | 2015-12-21 | 2017-12-26 | 神威药业集团有限公司 | The purposes of curcumin and Afatinib therapeutic alliance non-small cell lung cancer |
EP3433225B1 (en) * | 2016-06-13 | 2021-03-17 | China Medical University | Novel derivatives of curcuminoids and use thereof as an anticancer agent |
-
2021
- 2021-12-14 US US18/267,691 patent/US20240000742A1/en active Pending
- 2021-12-14 CA CA3205490A patent/CA3205490A1/en active Pending
- 2021-12-14 CN CN202180085228.3A patent/CN117120438A/en active Pending
- 2021-12-14 WO PCT/CN2021/137647 patent/WO2022127751A1/en active Application Filing
- 2021-12-14 TW TW110146701A patent/TWI798994B/en active
- 2021-12-14 JP JP2023538038A patent/JP2023554532A/en active Pending
- 2021-12-14 KR KR1020237024434A patent/KR20230131861A/en active Search and Examination
- 2021-12-14 EP EP21905680.1A patent/EP4265256A4/en active Pending
- 2021-12-14 AU AU2021402788A patent/AU2021402788A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230131861A (en) | 2023-09-14 |
CN117120438A (en) | 2023-11-24 |
TWI798994B (en) | 2023-04-11 |
WO2022127751A1 (en) | 2022-06-23 |
EP4265256A1 (en) | 2023-10-25 |
AU2021402788A9 (en) | 2024-05-16 |
US20240000742A1 (en) | 2024-01-04 |
AU2021402788A1 (en) | 2023-08-03 |
JP2023554532A (en) | 2023-12-27 |
EP4265256A4 (en) | 2024-06-12 |
TW202225136A (en) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110046211A1 (en) | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents | |
US20160271133A1 (en) | Methods of Treating Multiple Myeloma and Resistant Cancers | |
US11202779B2 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors | |
US11666574B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
CN104363913A (en) | CDK8/CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer | |
WO2011005790A1 (en) | Compositions and methods for inhibition of cancers | |
EP1968981B1 (en) | Azaxanthones and use thereof for treating tumors | |
EP3034076A1 (en) | Combined application of isothiocyanate compound and anti-cancer medicine | |
CA3205490A1 (en) | Use of pharmaceutical composition for treating lung cancer | |
AU2006223000B2 (en) | Methods of treating cancer using PPAR-gamma antagonists | |
SG174271A1 (en) | Treatment of pancreatic cancer | |
EP2298309B1 (en) | Antitumor agent, kit and method of treating cancer | |
WO2019184306A1 (en) | Target for drug treatment of tumor metastasis and use thereof | |
WO2002002094A2 (en) | Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy | |
Kaur et al. | A REVIEW ARTICLE ON ANTICANCER AGENTS AND USE OF STATINS AS POTENTIAL ANTICANCER DRUG | |
CN111067894A (en) | Application of miconazole in preparation of anti-squamous-lung-carcinoma drug and cisplatin sensitizer | |
KR20230146523A (en) | Treatment of breast cancer using combination therapy containing GDC-9545 and abemaciclib or ribociclib | |
Lukan | D Di is sc co ov ve er ry y, B Bi io ol lo og gy a an nd C Cl lin ni ic ca al A Ap pp pl lic ca at ti io on ns s | |
WO2003077909A1 (en) | Medical use of captopril for the treatment and prophylaxis of cancer | |
Nakahira et al. | 424 Proffered Papers | |
JP2017171640A (en) | Cancer therapeutic system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20230616 |
|
EEER | Examination request |
Effective date: 20230616 |
|
EEER | Examination request |
Effective date: 20230616 |
|
EEER | Examination request |
Effective date: 20230616 |